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Aim: The aim of this retrospective study was to investigate the clinical and histopatho-
logical characteristics of the disease and treatment outcome of patients with pure uterine
sarcomas.
Background: Uterine sarcomas are especially rare tumours, comprising only 3–5% of uterine
cancers. They are characterized by histopathological diversity, rapid clinical progression,
and  poor prognosis. Optimal management consists of complete surgical removal and adju-
vant  radiotherapy may improve the prognosis.
Materials and methods: All patients with pure uterine sarcoma histology treated at our centre,
the  Institut Català D’Oncologia in Barcelona Spain, between 2002 and 2010 were reviewed.
Results: Records of 17 patients treated at our hospital over an 8-year period were obtained.
Nine patients (53%) had leiomyosarcoma, 7 (41%) had endometrial stromal sarcoma, and 1
patient had unclassiﬁed sarcoma. All patients were treated with external beam radiation
after surgical excision. Mean age was 62 years (range, 51–69 years). Of the 17 patients, 13
(76%) presented with stage I disease, 2 (12%) were stage II, and 2 (12%) stage III. The overall
actuarial 2-year survival estimate was 82.5%. Two patients experienced local relapse. The
2-year local control rate was 90%. A total of 5 patients experienced either local or metastatic
relapse. The 2-year progression free survival rate was 58%.Conclusion: In our experience, combined treatment (surgery and adjuvant radiation therapy)
is  effective with acceptable side effects. Larger and multicenter studies are needed to assess
treatment outcome for pure uterine sarcoma histology.
©  2012 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
the characteristics of these neoplasms. Despite the rarity of.  Backgroundterine sarcomas are especially rare tumours, comprising only
–5% of uterine cancers.1 Because of their low incidence and
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the existence of various pathologic types, little is known aboutthis tumour, signiﬁcant progress has been made in recent
years in improving classiﬁcation, staging and management of
patients with uterine sarcoma.2
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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Fig. 1 – Kaplan–Meier estimates of local relapse free
survival among patients treated with surgery and adjuvant
A number of early reports showed improved local control
when post-operative adjuvant radiation was administered,
and in some of these early series this seemed to give an154  reports of practical oncology an
The current World Health Organization classiﬁcation of
tumours of the female genital tract divides uterine mes-
enchymal tumours into two types: smooth muscle tumours
and endometrial stromal tumours.3 Leiomyosarcoma (LMS)
is the most common uterine sarcoma arising within the
myometrium. LMS  is a malignant smooth muscle tumour,
and typically presents with prominent necrosis, high mitotic
index, and moderate to severe cytological atypia. Diagnosis
is based on a combination of some or all of these features.4
Endometrial mesenchymal tumours are considerably rarer
than smooth muscle uterine tumours. Endometrial stromal
sarcoma (ESS) is a densely cellular tumour whose classiﬁ-
cation has been changed in recent years. Since the extent
of mitotic activity within the tumour is more  closely corre-
lated with prognosis than the degree of cellular atypism, it
became apparent that such tumours should be separated into
two different clinicopathological entities: endometrial stro-
mal  sarcoma (ESS) and undifferentiated endometrial sarcoma
(UES).5,6 ESS is a ‘low grade’ tumour, behaving in an indolent
fashion irrespective of its mitotic index. In contrast, UES is a
‘high grade’, rapidly growing tumour, characterized by aggres-
sive behaviour and poor outcomes.7,8
In the last decade, the pathological description of uterine
sarcomas has experienced numerous changes. Carcinosar-
coma (CS), also called malignant mixed Müllerian tumour,
had traditionally been considered a sarcoma. CS is a biphasic
tumour, consisting of both carcinomatous epithelial and
malignant mesenchymal components.9 These two compo-
nents used to be assumed as separate, resulting in a ‘collision’
tumour. However, it is now clear that the epithelial and mes-
enchymal components derive from a single stem cell, with
the epithelial element of the tumour dominant in determining
the biological behaviour. CS has therefore been re-classiﬁed as
a dedifferentiated/metaplastic endometrial carcinoma,10 and
for this reason it is not included in our study.
Many risk factors for uterine sarcoma have been reported
in the literature. The most common factors associated with
higher risk for these sarcomas are previous pelvic irradiation
(most commonly more  than 10 years before tumour devel-
opment and reported in 10–25% of cases); black women; and
the use of long-term adjuvant tamoxifen for breast cancer.11,13
The clinical presentation of uterine sarcomas is non-speciﬁc.
Peak incidence is between 50 and 65 years of age. Uterine sar-
comas typically present as a rapidly growing uterine mass, and
additional symptoms may include pelvic or abdominal pain
and vaginal bleeding.14
Radiological diagnosis prior to hysterectomy is difﬁcult,
with diagnosis frequently made post-operatively.15 Current
staging systems have been unsatisfactory, although a FIGO
staging system created speciﬁcally for uterine sarcomas is
available, and may allow better grouping of patients accord-
ing to expected prognosis.16 The reported prognostic factors
in uterine sarcomas are as follows: stage, age, residual
tumour after surgery, positive peritoneal cytology, lymph node
involvement, vascular and lymphatic space invasion, myome-
trial invasion, degree of advanced differentiation or mitotic
17index, large tumour size, and pathologic type. Because
these tumours are so aggressive, the incidence rate of distant
metastases is quite high.18 Typically, disease spread occurs
locally; lymphatic spread is unusual in uterine sarcoma,external beam radiotherapy.
in which dissemination usually occurs in the peritoneum
and early haematogenous spread with distant metastases
(Figs. 1 and 2).19
Treatment of uterine sarcomas is a considerable challenge.
The primary treatment of early stage disease is total abdomi-
nal hysterectomy (TAH) with bilateral salpingo-oophorectomy
(BSO) and peritoneal washings; however, it is not clear whether
routine lymphadenectomy is necessary. External pelvic irra-
diation has been employed as adjuvant treatment, and most
authors report that this therapy decreases local recurrence
rates without any signiﬁcant impact on survival, given that
most patients with relapsed disease have distant failures.20–22Fig. 2 – Kaplan–Meier estimates of distant recurrence
failure among patients treated with surgery and adjuvant
external beam radiotherapy.
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Table 1 – International Federation of Gynaecology and
Obstetrics (FIGO, 2009) staging system for
Leiomyosarcoma and Endometrial Stromal Sarcoma.
Stage Deﬁnition
I Tumour limited to the uterus
IA ≤5 cm
IB >5 cm
II Tumour extends beyond the uterus, within the pelvis
IIA Adnexal involvement
IIB Involvement of other pelvic tissues
III Tumour invades abdominal tissues (not just protruding
into abdomen)
IIIA 1 Site
IIIB >1 Site
IIIC Metastasis to pelvic and/or para-aortic lymph nodes
IV
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Table 2 – Baseline characteristics.
N (%)
Menopausal status
Median age/range 62 (51–69)
Post-menopausal 17 (100%)
Medical history
HTA 9 (53%)
DM 0
Median between symptom and evaluation (days) 34 (5–122)
First symptom: menorrhagia 14 (85.7%)
Type of surgery
TAH and BSO 7 (41%)
TAH and BSO and node sampling 10 (59%)
FIGO stage
I 13 (76%)
II 2 (12%)
III 2 (12%)
Histological type
Leiomyosarcoma (LMS) 9 (53%)
Endometrial stromal sarcoma (ESS) 7 (41%)
Unclassiﬁed 1 (7%)
Tumour grade
Moderately differentiated (G2) 5 (29%)
Poorly differentiated (G3) 8 (47%)
Unknown 4 (24%)
Myometrial invasion
Inner third 6 (35%)IVA Tumour invades bladder/or Rectum
IVB Distant metastases
mproved survival beneﬁt compared to surgery alone.10,23 The
ole of complementary brachytherapy in these patients is
nclear and somewhat controversial, given the lack of avail-
ble data on local outcome.
Most of the previous studies of uterine sarcomas included
atients with CS. Given the recent changes in the classiﬁca-
ion, it is apparent that new studies are needed to evaluate
nd characterize pure uterine sarcomas, especially consider-
ng how rare they are. For this reason, we decided to undertake
he present study.
The objective of our study was to assess the clinical evolu-
ion of a group of patients from our centre who had undergone
urgery and adjuvant radiotherapy to treat uterine sarcomas
LMS, ESS, UES). We  assessed local control, distant metastasis,
nd overall and progression-free survival.
.  Materials  and  methods
he study included all 17 patients treated at our hospital for
terine sarcoma between May 2002 and July 2010. Patient med-
cal records were reviewed, and information regarding patient
edical history, tumour characteristics, treatment modali-
ies, and follow-up was recorded. Survival information was
btained by personal consultation. All patients were staged
etrospectively according to the 2009 FIGO staging classiﬁca-
ion (Table 1).
Follow-up examinations were usually performed every 3
onths during the ﬁrst 2 years, every 4 months during the
hird year, every 6 months until the ﬁfth year, and annually
hereafter. Follow-up visits included a physical examination
nd, depending on the treatment protocol and the existence
f clinical symptoms, chest X-ray and/or abdominal and pelvic
omputed tomography to rule out recurrent or metastatic dis-
ase.
.1.  Statistical  analysis
he data were analysed using SAS software version 9.2 (SAS
nstitute, Cary, NC). The main endpoints were overall survival,
ocal control, and progression free-survival. All estimates were
alculated using the Kaplan–Meier estimator. We were unableMiddle third 2 (12%)
Outer third 9 (53%)
to evaluate the prognostic factors due to the small sample size.
Frequency table are present for prognostic factors, treatment,
efﬁcacy and toxicity.
3.  Results
The clinical characteristics of all patients are presented in
Table 2. Mean age was 62 years (range, 51–69). Nine patients
(53%) had leiomyosarcoma, seven (41%) had endometrial stro-
mal  sarcoma and one patient had unclassiﬁed sarcoma. All
patients were post-menopausal.
Family history was mostly of breast cancer, although some
patients also had a family history of uterine adenocarcinoma
and gastrointestinal malignancies. Half of the patients had
arterial hypertension (HTA). The main presenting symptom
was abnormal uterine bleeding (metrorrhagia), although other
symptoms, including abdominal pain or discomfort, were also
described. Time from symptom presentation to diagnosis was
highly variable, ranging from 5 to 122 days, although in cases
of postmenopausal bleeding, the time to diagnosis was sub-
stantially shorter (median, 33 days).
All 17 patients were treated surgically with curative
intent; of these, 7 patients (41%) underwent total abdominal
hysterectomy with bilateral salpingo-oophorectomy and
peritoneal washings, without pelvic lymphadectomy. Node
sampling was performed in 10 patients (59%), and in 4 cases
lymph nodes were dissected laparoscopically. Postoperative
evaluation revealed no additional malignancy, although 1
patient had a positive peritoneal washing. Remarkably, the
156  reports of practical oncology and rad
Table 3 – Radiation therapy details.
N (range)
Whole pelvis RT
Total dose 50.4 (45–50.4)
Duration of WPRT (days) 38 (34–55)
Duration of WPRT + BT (days) 53 (32–86)
Dose (Gy) per fraction 1.8 (1.8–2.0)
Four ﬁelds 17 (100%)
Energy 15 (15–18 MV)
Brachytherapy
LDR 7 (50%)
which also recurred locally, but the presence of a positivePDR 4 (28.6%)
HDR 3 (21.4%)
histological analysis showed that the surgical margins were
free of disease in all cases (R0).
Most patients (13 of 17; 76%) presented with stage I dis-
ease: 11 of these patients were diagnosed with stage IA and
2 patients with stage 1B. The other 4 patients were stage II (2
cases) or stage III (2 cases). No stage IV patients were included
in this sample. Eight patients (47%) had a Grade 3/poorly differ-
entiated tumour, 5 (29%) a Grade 2/moderately differentiated
tumour, and 4 patients (24%) had unknown tumour grading.
All patients underwent external beam radiotherapy (EBRT)
with linear accelerator and a mean dose of 50.4 Gy (45–50.4 Gy)
in several daily fractions (Table 3). In addition, 14 patients
received intracavitary vaginal brachytherapy after EBRT. The
mean dose of brachytherapy was 25.5 Gy (10–36 Gy). High-
dose-brachytherapy was used in only 3 patients. One patient
also received chemotherapy (combined ifosphamide and adri-
amycin) due to positive peritoneal malignancy.
Side-effects and toxicity were as expected in such cases,
with no grade 3 (RTOG/EORTC acute and late toxicity morbid-
ity scoring criteria) gastro-intestinal or genito-urinary toxicity
during treatment or follow-up.16,17 The most common acute
side effects were grade 2 gastro-intestinal toxicity, reported in
6 patients during treatment. Eight patients experienced acute
urinary toxicity (≤ grade 2) during treatment. There were no
cases requiring interruption of adjuvant radiotherapy due to
treatment toxicity. Possible late side effects of radiotherapy
were observed in 3 patients who reported gastro-intestinal
pain (one of which was scored as a RTOG/EORTC grade 3 tox-
icity). Notably, all 3 of these patients had undergone adjuvant
low-dose rate brachytherapy, although the total cumulative
dose delivered to the rectum and bowel was ≤70 Gy in all 3
cases.
Median follow-up was 43 months during which one case of
local recurrence and 4 cases of distant metastasis in the lung
were observed.
The overall 2-year actuarial survival estimate was 82.5%.
Two patients suffered a local relapse. The 2-year local control
rate was 90%. A total of 5 patients experienced either local
or metastatic relapse. Progression free survival at 2 years was
58%.
4.  DiscussionUterine sarcoma is a rare and lethal disease. The data pre-
sented here are derived from a small series of patients treatediotherapy 1 8 ( 2 0 1 3 ) 153–158
at our department over a 10-year period. Carcinosarcomas,
which account for approximately half of uterine sarcomas
in other studies, are no longer considered pure sarcomas
due to recent changes in histological classiﬁcation.10,13,23,24
As a result of the exclusion of this histological sub-group,
our series consists of only 17 patients. However, to our
knowledge, ours is one of the ﬁrst studies to evaluate and
characterize pure sarcomas and treatment outcome under
this new classiﬁcation system.
Age distribution was similar regardless of histological sub-
type, since all the women were post-menopausal. One woman
had a history of breast cancer treated by tamoxifen for 5 years.
As previous studies have described, the use of tamoxifen is
associated with an increased risk for uterine sarcoma, mainly
CS.11,12 None of the patients in our sample had previously
undergone pelvic irradiation.
Time between ﬁrst symptom and ﬁrst medical evaluation
was highly variable (between 5 and 122 days). Despite this wide
range, the median time elapsed between ﬁrst symptom and
diagnosis was only 34 days, probably because the most com-
mon  initial symptom in our study was vaginal bleeding (85%),
which usually leads to a faster diagnosis.
We cannot draw any conclusions about the efﬁcacy of
chemotherapy in this group because only 1 patient received
this adjuvant treatment.
As described in previous studies, the only factor that was
signiﬁcantly correlated with prognosis was disease stage at
diagnosis.12,14 However, we should point out that the limited
number of patients in our study made it difﬁcult to ﬁnd a sig-
niﬁcant correlation between risk factors and prognosis. In our
study, 76% of patients were stage I, a bit lower than the 84.8%
reported in the EORTC study.24 The good response to treatment
observed in our sample was likely to be related to the early
stage disease, and this is supported by the relatively small
number of patients who experienced local recurrence (2 cases)
and/or distant metastasis to the lung (4 patients). Notably, all
4 of the patients with distant metastasis had a poor histolog-
ical prognosis (more than 20 mitoses/ﬁeld) and presence of
vascular invasion.
Vascular and lymphatic invasion is a well-known progno-
stic factor in several diseases because the penetration gives
tumour cells the opportunity to metastasize to other sites.
In general terms, invasion of vascular spaces by a tumour is
indicative of an aggressive neoplasm that has a marked ten-
dency to metastasize and to recur locally.18 In a study of 60
patients diagnosed with uterine neoplasms with sarcomatous
component, Rovirosa et al.19 found that vascular and lym-
phatic space invasion is the most relevant prognostic factor
after staging.
We  found that, based on histological group, LMS patients
had a worse outcome than ESS patients. Patients with uterine
LMS  accounted for 3 of the 4 cases of distant metastasis
and 1 of the 2 cases with local recurrence. Ferrer et al.25,
in a study that included 103 patients, found that uterine
LMS  patients had a poorer prognosis when adjusted for age.
The other patient with lung metastasis had uterine ESS,peritoneal washing in surgery could have contributed to that
patient’s poor outcome. All patients with speciﬁc disease
recurrence were classiﬁed initially as FIGO stage III, which
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ay have contributed to the poor clinical outcome in our
eries. It should be noted that the distant lung metastases all
ccurred shortly after the end of treatment (between 60 and
60 days after radiotherapy), a fact that appears to support
he aggressive behaviour of these tumours.
The low treatment toxicity rate reported in our series is
lso notable, although it is important to remember that this
as a retrospective study. That said, we believe that toxicity
ould be further reduced with the use of newer radiotherapy
echniques such intensity modulated radiotherapy (IMRT) or
elical tomotherapy (HT). Yang et al. found that IMRT  and
T deliver better conformity and lower dose to organs at risk
s. 3D conformal radiotherapy in postoperative whole pelvic
adiotherapy (WPRT) for endometrial cancer. Nevertheless, the
mpact of these radiotherapy techniques on toxicity has yet to
e assessed in a prospective study.26
Surgery is the primary treatment for localized uterine
arcomas. The use of lymphadenectomy is a bit more  con-
roversial, especially in pure uterine sarcomas (LMS and ESS),
hich tend not to spread to the lymph nodes. In one series
f 275 women with uterine LMS,  only 3 of 37 patients who
nderwent nodal sampling had positive nodes,27 suggesting
hat lymphadenectomy should be performed only for CS his-
ology. In our study, in which 10 patients underwent nodal
ampling, all the nodal biopsies were negative.
The only randomized study of adjuvant radiotherapy in
terine sarcomas was published by the EORTC.24 In that study,
atients underwent surgery and were randomized either to
bservation or pelvic radiation. Adjuvant chemotherapy was
ot administered. There were almost as many  patients with
MS  as those with CS (103 and 91, respectively). The initial
nalysis showed a reduction in local relapse in the radiothe-
apy arm (22% vs. 40%). Local recurrence was low (2.7% of
atients) while 44.5% of patients had distant metastasis dur-
ng follow-up. Compared to our study, the local recurrence rate
as lower but distant metastasis higher. The EORTC study
ound no difference in overall or disease-free survival between
he groups, although a subgroup analysis revealed improved
ocal control for CS patients who had undergone radiothe-
apy, but no beneﬁt for the LMS  radiotherapy subgroup. This
esult may be due to increased radiotherapy effectiveness on
arcinomatose component of the CS.
Most patients (82%) in our series underwent adjuvant
rachytherapy after completing external pelvic irradiation,
ut the use of brachytherapy in vaginal fundus is highly vari-
ble depending on the centre. To our knowledge, no study
ublished to date has been able to demonstrate better local
ontrol with brachytherapy; notwithstanding this lack of date,
e recommend its use as a boost technique because it pro-
ides improved localized dose distribution with the potential
o destroy sub-clinical disease with minimal early and late
orbidity.28–30
.  Conclusionlthough our study was too small to obtain statistically
igniﬁcant results, we believe the ﬁndings presented here
ontribute to the growing body of evidence in this rare tumour
ype. However, it is clear that large multicenter studies will be
1therapy 1 8 ( 2 0 1 3 ) 153–158 157
necessary to gain a better understanding of uterine sarcoma.
Nevertheless, with the exclusion of CS even less patients will
contribute for future studies. In our experience, disease stage,
LMS histology, and vascular invasion all seem to be relevant
for prognosis. As described in literature, no other treatment
modality seems to be as effective as hysterectomy with
bilateral oophorectomy and adjuvant radiation therapy. Side
effects of combined surgery and irradiation are acceptable,
since severe side effects are rare.
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